F. Cognetti

发表

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations.

R. Foà, S. Chiaretti, G. Zupi, 2009, Neoplasia.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

A. Marchetti, F. Buttitta, P. Visca, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011, Clinical Cancer Research.

A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.

M. Biffoni, C. Peschle, G. Mariani, 2007, Gynecologic oncology.

The protective side of progesterone

F. Cognetti, G. Ferretti, A. Felici, 2007, Breast Cancer Research.

A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).

J. Sehouli, F. Cognetti, N. Colombo, 2013, Gynecologic oncology.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma

M. Mottolese, S. Di Cosimo, M. Milella, 2005, Cancer.

Effect of Filgrastim on Serum Lactate Dehydrogenase and Alkaline Phosphatase Values in Early Breast Cancer Patients

S. Di Cosimo, F. Cognetti, A. Fabi, 2004, Cancer investigation.

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.

F. Cognetti, A. Fabi, P. Carlini, 2007, Bone.

Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.

M. Milella, F. Cognetti, F. Facciolo, 2006, Cancer treatment reviews.

ResearchMagnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer : meta-analysis of randomized clinical trials

P. Muti, M. Milella, F. Cognetti, 2015 .

New approaches to prevent intestinal toxicity of irinotecan-based regimens.

A. Vecchione, A. Alimonti, F. Cognetti, 2004, Cancer treatment reviews.

Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.

F. Cognetti, A. Fabi, P. Carlini, 2006, Cancer treatment reviews.

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.

S. Barni, P. Bruzzi, M. Ceppi, 2017, European journal of cancer.

Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors.

F. Cognetti, D. Giannarelli, A. Annovazzi, 2020, Clinical nuclear medicine.

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.

R. Foà, M. Konopleva, M. Andreeff, 2007, Blood.

Role of mTOR Signaling in Tumor Microenvironment: An Overview

M. Milella, L. Ciuffreda, F. Cognetti, 2018, International journal of molecular sciences.

Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Oncology.

Piroxicam and Cisplatin in a Mouse Model of Peritoneal Mesothelioma

L. Altucci, J. Chien, G. Cortese, 2006, Clinical Cancer Research.

Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I–II clinical trial

F. Cognetti, A. Fabi, S. Tomao, 1999, Cancer Chemotherapy and Pharmacology.

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

M. Maschio, F. Cognetti, A. Fabi, 2009, BMC Cancer.

Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study

F. Cognetti, A. Fabi, G. Arcangeli, 2008, Journal of Neuro-Oncology.

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

D. Trisciuoglio, G. Zupi, M. Milella, 2006, Cancer research.

Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients

S. Ricci, S. Di Cosimo, A. Alimonti, 2007, Cancer investigation.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

Clinical Significance of PTEN and p-Akt Co-Expression in HER2-Positive Metastatic Breast Cancer Patients Treated with Trastuzumab-Based Therapies

M. Mottolese, M. Milella, F. Cognetti, 2010, Oncology.

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

P. Ascierto, A. Testori, E. Simeone, 2014, Journal of Translational Medicine.

Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression.

G. Citro, A. Baldi, S. Bosari, 2006, The international journal of biochemistry & cell biology.

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?

F. Cognetti, A. Annovazzi, V. Ferraresi, 2021, Frontiers in Oncology.

Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR

G. Tortora, M. Milella, F. Cognetti, 2012, Expert review of anticancer therapy.

Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

F. Cognetti, L. Serrone, M. Zeuli, 2000, Journal of experimental & clinical cancer research : CR.

HER 2 change between primary and metastatic breast cancer 1 HER 2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER : SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Predictive Biomarkers and Personalized Medicine HER 2 Protein and Gene Variation between Primary and Metastatic Breast Cancer : Significance and Impact on Patient Care

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Bevacizumab: one treatment for all the seasons?

F. Cognetti, A. Gelibter, M. Zeuli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer

F. di Costanzo, A. Gabriele, F. Cognetti, 2007, Current medical research and opinion.

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study

M. Maschio, F. Cognetti, A. Fabi, 2010, Journal of Neuro-Oncology.

Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?

A. Ceribelli, M. Mottolese, S. Di Cosimo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma

F. Cognetti, D. Giannarelli, F. Cuppone, 2005, Cancer.

Gender effects of single nucleotide polymorphisms and miRNAs targeting clock-genes in metastatic colorectal cancer patients (mCRC)

M. Mottolese, A. Torsello, M. Magnani, 2016, Scientific Reports.

Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin–paclitaxel in metastatic breast cancer patients

F. Cognetti, S. Tomao, I. Sperduti, 2007, Anti-Cancer Drugs.

Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?

M. Mandalà, M. Milella, F. Cognetti, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Medical Oncology And

M. Mandalà, M. Milella, F. Cognetti, 2022 .

NEMESI: A retrospective observational longitudinal study to investigate italian early breast cancer (EBC) patient characteristics and treatment.

V. Adamo, F. Cognetti, A. Gardini, 2010 .

Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow?

F. Cognetti, A. Fabi, P. Carlini, 2006, Cancer investigation.

Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy

S. Barni, R. Labianca, G. Luporini, 2005, Tumori.

Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.

F. Cognetti, P. Carlini, D. Giannarelli, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.

A. Testori, P. Gascón, C. Garbe, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

P. Fasching, R. Greil, R. Kreienberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

D. Crivellari, F. Montemurro, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in locally advanced stage ib 2-iib cervical cancer patients after neoadjuvant chemotherapy

F. Cognetti, R. Fruscio, F. Tomao, 2010 .

Pharmacokinetics of Gemcitabine at Fixed-Dose Rate Infusion in Patients with Normal and Impaired Hepatic Function

A. Sacconi, G. Citro, M. Milella, 2009, Clinical pharmacokinetics.

The Employment of Genera Vaccinium, Citrus, Olea, and Cynara Polyphenols for the Reduction of Selected Anti-Cancer Drug Side Effects

F. Cognetti, F. Bosco, J. Maiuolo, 2022, Nutrients.

Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers

F. Cognetti, I. Sperduti, A. Savarese, 2009, Journal of experimental & clinical cancer research : CR.

Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma

C. Gridelli, A. Ceribelli, F. de Marinis, 2003, Cancer.

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

A. Ceribelli, P. Marchetti, R. Chiari, 2021, Tumori.

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

P. Bruzzi, D. Merlo, F. Cognetti, 2013, BMC Cancer.

PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy

M. Mottolese, F. Cognetti, P. Natali, 2004, Clinical Cancer Research.

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.

M. Mottolese, F. Cognetti, A. Fabi, 2006, European journal of cancer.

Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.

M. Mandalà, F. Cognetti, A. Fabi, 2007, Thrombosis Research.

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Chest.

Adjuvant chemotherapy in muscle‐invasive bladder carcinoma

M. Gallucci, F. Cognetti, P. Carlini, 2006, Cancer.

Zoledronic Acid and Angiogenesis

F. Cognetti, A. Fabi, S. Tomao, 2007, Clinical Cancer Research.

Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer.

B. Casini, M. Diodoro, M. Mottolese, 2010 .

The other side of p53.

F. Cognetti, G. Ferretti, A. Felici, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.

G. Arpino, F. Cognetti, A. Fabi, 2019, Clinical breast cancer.

Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate

L. Strigari, P. Marchetti, F. Cognetti, 2017, Anti-cancer drugs.

Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome

G. Ciliberto, G. Sanguineti, F. Cognetti, 2020, Journal of experimental & clinical cancer research : CR.

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule.

F. Cognetti, A. Fabi, P. Carlini, 2008, Anticancer research.

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

Factorial design for randomized clinical trials.

F. Cognetti, M. Di Maio, D. Giannarelli, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Lineage-specific hematopoietic growth factors.

F. Cognetti, G. Ferretti, P. Papaldo, 2006, The New England journal of medicine.

Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?

S. Di Cosimo, A. Alimonti, F. Cognetti, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample

F. Cognetti, A. Savarese, A. Caruso, 2008, Journal of experimental & clinical cancer research : CR.

Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial.

C. Boni, S. Palazzo, F. Cognetti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.

C. Porta, G. Tortora, M. Milella, 2015, Critical reviews in oncology/hematology.

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.

F. Cognetti, A. Lombardi, G. Atlante, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.

A. Ceribelli, M. Milella, F. Cognetti, 2006, The Lancet. Oncology.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

G. Arpino, D. Generali, K. Cannita, 2017, Future oncology.

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition

S. Shirasawa, M. Milella, L. Ciuffreda, 2022, Frontiers in Oncology.

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

L. Landi, L. Crinò, M. Tiseo, 2019, European journal of cancer.

Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.

D. Amadori, M. Marangolo, M. Tonato, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.

F. Cognetti, P. Carlini, E. Conti, 1984, European journal of cancer & clinical oncology.

Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.

A. Favero, C. Boni, M. Tonato, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

353 MEK blockade converts AML differentiating response to retinoic acid (RA) into extensive apoptosis: involvement of Bcl-2 modulation and ROS accumulation

M. Konopleva, M. Andreeff, M. Milella, 2004 .

Does CTLA4 influence the suppressive effect of CD25+CD4+ regulatory T cells?

M. Pino, F. Cognetti, G. Ferretti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

extensive apoptosis MEK blockade converts AML differentiating response to retinoids into

M. Konopleva, M. Andreeff, S. Collins, 2013 .

Factors associated with an individuals’ decision to withdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are personality traits involved?

A. Martayan, F. Cognetti, A. Savarese, 2011, Familial Cancer.

Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.

M. Picardo, A. Baldi, F. Cognetti, 2013, Future oncology.

Results of EORTC phase III trial 22931 comparing, postoperatively, radiotherapy (RT) to concurrent chemo-radiotherapy (RT-CT) with high dose cisplatin in locally advanced head and neck (H&N) carcinomas (SCC)

V. Budach, M. Glabbeke, M. Bolla, 2001 .

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

P. Ascierto, E. Simeone, P. Queirolo, 2014, Journal of Neuro-Oncology.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases

F. de Marinis, A. Santoro, P. Marchetti, 2019, AntiCancer Research.

Transforming Growth Factor-β Signaling and Regulatory T Cells

M. Mandalà, F. Cognetti, G. Ferretti, 2007 .

Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

F. Cognetti, P. Carlini, D. Giannarelli, 2007, Journal of the National Cancer Institute.

Does low-molecular-weight heparin influence cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2006, Annals of Oncology.

Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality

F. Cognetti, P. Carlini, D. Giannarelli, 2005 .

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

G. Ciliberto, G. Blandino, G. Piaggio, 2021, Vaccines.

Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.

P. Visca, B. Casini, M. Diodoro, 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

C. Porta, F. Cappuzzo, C. Sternberg, 2019, Journal of Immunotherapy for Cancer.

The Experience of Oncology Healthcare Providers in the Central Italy during the COVID-19 Lockdown

G. Ciliberto, B. Vincenzi, F. Cognetti, 2020, Cancers.

Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.

C. Leonetti, M. Picardo, F. Cognetti, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer.

G. Arpino, K. Cannita, F. Montemurro, 2018, Breast.

Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor.

M. Fiore, F. Cognetti, M. D. Simone, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): Meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit

F. Cognetti, V. Lorusso, P. Carlini, 2007 .

Is delayed chemotherapy-induced emesis well managed in oncological clinical practice?

G. Tonini, F. Cognetti, A. Fabi, 2003, Supportive Care in Cancer.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

M. Pino, M. Milella, F. Cognetti, 2010, The oncologist.

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer

F. Cognetti, D. Giannarelli, F. Pimpinelli, 2022, Annals of Oncology.

Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?

R. Labianca, F. Cognetti, F. Loupakis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison.

F. Cognetti, D. Giannarelli, E. Bria, 2007, European urology.

Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis

A. Favero, R. Garbelli, M. Tonato, 1992 .

Cumulative or Delayed Nephrotoxicity after Cisplatin (DDP) Treatment

F. Cognetti, M. Giovannelli, P. Carlini, 1986, Tumori.

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.

S. Pignata, F. Cognetti, G. Scambia, 2019, Gynecologic oncology.

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)

F. Costanzo, A. Gabriele, F. Cognetti, 2004 .

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC).

F. di Costanzo, A. Gabriele, F. Cognetti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy

A. Delmonte, R. Chiari, F. Cognetti, 2016 .

HER2 change between primary and metastatic breast cancer 1 HER2 PROTEIN AND GENE VARIATION BETWEEN PRIMARY AND METASTATIC BREAST CANCER: SIGNIFICANCE AND IMPACT ON PATIENT CARE

M. Mottolese, F. Cognetti, A. Fabi, 2011 .

Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

F. Cognetti, A. Fabi, P. Carlini, 2001, Cancer Chemotherapy and Pharmacology.

How to restructure the management of Italian oncological patients during and after COVID-19 pandemic?

F. Cognetti, A. Fabi, G. Ferretti, 2020, European review for medical and pharmacological sciences.

Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.

A. Sacconi, G. Citro, M. Milella, 2009, Clinical pharmacokinetics.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time? A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials.

A. Ceribelli, M. Pino, M. Milella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.

O. Dalesio, F. Cognetti, M. Rozencweig, 1986, European journal of cancer & clinical oncology.

Changes in HER2 overexpression between primary tumor and autologous metastases: Correlations with clinical and biological features

M. Mottolese, F. Cognetti, A. Fabi, 2008 .

HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?

M. Mandalà, S. Di Cosimo, A. Alimonti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostaglandin E2 drives cyclooxygenase 2 expression via cyclic AMP response element activation in human pancreatic cancer cells

M. Pino, D. McConkey, F. Cognetti, 2005, Cancer biology & therapy.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

F. Roila, D. Generali, F. Montemurro, 2017, The oncologist.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme

C. Porta, C. Sternberg, S. Pignata, 2018, BJU international.

Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.

F. Cognetti, D. Giannarelli, V. Ferraresi, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-2, Interferon-α and Interleukin-2 plus Interferon-α in Renal Cell Carcinoma. A Randomized Phase Ii Trial

F. Cognetti, F. Boccardo, A. Rubagotti, 1998, Tumori.

Darbepoetin alfa and history of thromboembolic events.

F. Cognetti, G. Ferretti, A. Felici, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in previously untreated melanoma without BRAF mutation.

D. Schadendorf, K. Savage, C. Horak, 2015, The New England journal of medicine.

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

D. Schadendorf, K. Savage, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials.

M. Milella, F. Cognetti, F. Loupakis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zoledronic acid-associated thrombotic thrombocytopenic purpura.

F. Cognetti, A. Fabi, P. Carlini, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.

G. Mariani, U. Testa, F. Cognetti, 2010, International journal of oncology.

Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis

F. Cognetti, A. Fabi, A. Vidiri, 2018, In Vivo.

Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

F. Cognetti, A. Fabi, A. Vidiri, 2018, Oncology.

Testis metastasis as an initial manifestation of an occult gastrointestinal cancer.

A. Vecchione, F. Marandino, F. Cognetti, 2004, Anticancer research.

Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial

G. Muto, M. Gallucci, F. Cognetti, 2008 .

Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

C. Porta, G. Tortora, M. Milella, 2013, Clinical genitourinary cancer.

Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOL.

F. di Costanzo, F. Mazzoni, F. Cognetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.

F. Cognetti, A. Fabi, A. Vidiri, 2009, Anticancer research.

Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme

M. Maschio, F. Cognetti, A. Fabi, 2009, Cancer Chemotherapy and Pharmacology.

Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases

F. Cognetti, M. P. Cicini, C. Nisticò, 2021, Breast Care.

Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study.

F. Cognetti, G. Atlante, F. Calabresi, 1997, American journal of clinical oncology.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

D. Generali, F. Cognetti, A. Fabi, 2015, Future oncology.

Palbociclib: efficacious but predictive biomarkers still needed.

F. Cognetti, D. Alesini, P. Malaguti, 2016, The Lancet. Oncology.

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

F. Cognetti, A. Fabi, P. Carlini, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?

F. Cognetti, D. Giannarelli, E. Cortesi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.

F. Cognetti, V. Ferraresi, C. Botti, 1994, European journal of cancer.

α‐tocopherol protects against cisplatin‐induced toxicity without interfering with antitumor efficacy

C. Leonetti, M. Scarsella, G. Zupi, 2003, International journal of cancer.

Neuroprotective E ffect o f V itamin E S upplementation i n Patients T reated W ith C isplatin C hemotherapy

C. Leonetti, M. Picardo, F. Cognetti, 2003 .

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

F. Cognetti, A. Fabi, D. Giannarelli, 2008, Supportive Care in Cancer.

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

M. Pino, D. McConkey, J. Abbruzzese, 2006, Cancer research.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Jacques Bernier, Michel Bolla, Mahmut Ozsahin, 2004, The New England journal of medicine.

PTEN: Multiple Functions in Human Malignant Tumors

M. Milella, L. Ciuffreda, F. Cognetti, 2015, Front. Oncol..

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study

G. Arpino, P. Marchetti, F. Cognetti, 2013, ClinicoEconomics and outcomes research : CEOR.

Clinicoeconomics and Outcomes Research

G. Arpino, P. Marchetti, F. Cognetti, 2022 .

Nutraceuticals and Cancer: Potential for Natural Polyphenols

F. Cognetti, F. Bosco, J. Maiuolo, 2021, Nutrients.

Early recurrence risk: aromatase inhibitors versus tamoxifen

M. Milella, F. Cognetti, P. Carlini, 2010, Expert review of anticancer therapy.

Is there a benefit by the sequence anastrozole–formestane for postmenopausal metastatic breast cancer women?

S. Cosimo, F. Cognetti, A. Fabi, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

M. Milella, L. Ciuffreda, F. Cognetti, 2020, Cancers.

Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study

A. Torsello, F. Cognetti, P. Pezzotti, 2020, Frontiers in Oncology.

Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology

A. Scarpa, C. Luchini, M. Milella, 2020, International journal of molecular sciences.

Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients

F. Marandino, C. Zoccali, F. Cognetti, 2010, BMC Cancer.

Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer

Fiorella Guadagni, Patrizia Ferroni, Mario Roselli, 2001, Breast Cancer Research and Treatment.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck

A. Graeff, J. Verweij, J. Schornagel, 1996 .

Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group.

S. Rodenhuis, G. Snow, J. Verweij, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

M. Mottolese, F. Cognetti, A. Fabi, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients

E. Vasile, G. Fasola, D. Galetta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.

J. Clohessy, P. Pandolfi, H. Scher, 2010, The Journal of clinical investigation.

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

J. McCubrey, G. Tortora, F. Ciardiello, 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer

A. Scarpa, C. Luchini, V. Corbo, 2020, Cells.

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer

G. Ciliberto, E. Pescarmona, F. Cognetti, 2021, Molecular cancer.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

A. Ceribelli, G. Tortora, M. Milella, 2013, Expert opinion on drug discovery.

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response

G. Ciliberto, E. Gallo, F. Cognetti, 2021, International journal of molecular sciences.

PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting.

M. Milella, L. Ciuffreda, F. Cognetti, 2014, Advances in biological regulation.

Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group.

J. Verweij, J. Schornagel, F. Cognetti, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Bio-pathologic Characteristics Related to Chromosome 11 Aneusomy and Cyclin D1 Gene Status in Surgically Resected Stage I and II Breast Cancer: Identification of an Adverse Prognostic Profile

M. Mottolese, F. Cognetti, R. Merola, 2007, The American journal of surgical pathology.

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

G. Giaccone, V. Torri, G. Scagliotti, 2003, Journal of the National Cancer Institute.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

Future directions in the second-line treatment of non-small cell lung cancer.

R. Rosell, M. Taron, N. Reguart, 2006, Seminars in oncology.

Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.

F. di Costanzo, A. Gamboni, F. Cognetti, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

mTOR Cross-Talk in Cancer and Potential for Combination Therapy

M. Milella, L. Ciuffreda, F. Cognetti, 2018, Cancers.

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

G. Scagliotti, A. Ceribelli, M. Milella, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients

F. Marincola, E. Wang, F. Cognetti, 2009, International journal of cancer.

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

M. Milella, F. Cognetti, P. Carlini, 2006, Cancer.

AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

M. Milella, L. Ciuffreda, F. Cognetti, 2020, International journal of molecular sciences.

Ras oncogene mutations and survival in patients with lung cancer

F. Cognetti, G. Ferretti, A. Felici, 2006, British Journal of Cancer.

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

G. Tortora, M. Pino, D. Melisi, 2011, Expert opinion on therapeutic targets.

Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.

R. Gralla, M. Milella, F. Cognetti, 2009, Lung cancer.

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise?

M. Fanciulli, M. Milella, L. Ciuffreda, 2019, Cancers.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

Stephen L. Abrams, A. Marchetti, R. Foà, 2012, Journal of Molecular Medicine.

Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination

F. Cognetti, P. Carlini, E. Ruggeri, 2004, Cancer Chemotherapy and Pharmacology.

Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study

F. Cognetti, D. Giannarelli, V. Ferraresi, 2008, Cancer Chemotherapy and Pharmacology.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

F. Cognetti, A. Fabi, M. Infante, 2019, Journal of Experimental & Clinical Cancer Research.

Systemic Therapy in Melanoma

M. Pino, F. Cognetti, C. Nuzzo, 2014 .

Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer

G. Tortora, V. Zagonel, F. Cognetti, 2012, Cancer.

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy

F. Cognetti, A. Barnabei, A. Chiefari, 2020, Frontiers in Endocrinology.

Colorectal cancer stem cells properties and features: evidence of interleukin-8 involvement

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Cancer drug resistance.

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?

M. Maschio, V. Zagonel, F. Cognetti, 2019, Future oncology.

Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.

A. Vecchione, A. Alimonti, F. Cognetti, 2005, Anticancer research.

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.

M. Ceppi, F. Puglisi, O. Garrone, 2020, European journal of cancer.

Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials

P. Muti, M. Milella, F. Cognetti, 2010, BMC Cancer.

Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?

M. Milella, F. Cognetti, P. Carlini, 2009, Cancer.

The clinician’s perspective on the 21-gene assay in early breast cancer

F. Cognetti, G. Naso, 2021, Oncotarget.

Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).

A. Rossi, C. Gridelli, A. Russo, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience.

V. Adamo, G. Colucci, F. Cognetti, 2012, European journal of cancer.

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

P. Ascierto, A. Testori, E. Simeone, 2014, Cancer investigation.

Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.

A. Graeff, J. Verweij, J. Schornagel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer

F. Cognetti, P. Carlini, D. Giannarelli, 1988, Cancer.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

A. Marchetti, F. Buttitta, S. Iacobelli, 2009, Neoplasia.

Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial.

M. Maschio, F. Cognetti, A. Fabi, 2021, Future oncology.

The Real-Life Journey of Elderly Patients in Soft Tissue and Bone Sarcomas: A Retrospective Analysis from a Sarcoma Referral Center

E. Pescarmona, C. Zoccali, F. Cognetti, 2020, Journal of clinical medicine.

Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients.

G. Arpino, F. Cognetti, A. Fabi, 2020, Future oncology.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

L. Landi, G. Minuti, F. Cappuzzo, 2019, Journal of Immunotherapy for Cancer.

Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.

C. Leonetti, M. Picardo, F. Cognetti, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic pancreatic cancer: Is there a light at the end of the tunnel?

M. Reni, A. Scarpa, G. Tortora, 2015, World journal of gastroenterology.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

M. Milella, F. Cognetti, L. Moscetti, 2013, World journal of gastroenterology.

SUDDEN DEATH AFTER ACUTE DYSTONIC REACTION TO HIGH-DOSE METOCLOPRAMIDE

F. Cognetti, M. Nardi, C. F. Pollera, 1984, The Lancet.

Cardiac tamponade as the initial manifestation of extracardiac malignancy.

F. Cognetti, M. C. Cercato, G. la Ferla, 1991, European journal of cancer.

High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide.

M. Sporn, M. Biffoni, M. Russo, 2009, Cancer letters.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

A. Scarpa, V. Corbo, S. Shirasawa, 2018, Journal of experimental & clinical cancer research : CR.

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

M. Pino, M. Milella, F. Cognetti, 2009, Oncology.

Cancer in the elderly: why so badly treated?

I. Fentiman, M. Aapro, S. Monfardini, 1990, The Lancet.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues.

A. Rossi, S. Verma, G. Tonini, 2008, Expert opinion on biological therapy.

The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?

F. Cognetti, A. Fabi, D. Giannarelli, 2017, Breast.

Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.

F. Puglisi, O. Garrone, F. Montemurro, 2022, The Lancet. Oncology.

A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.

F. Guadagni, S. Carlini, F. Cognetti, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.

M. Mottolese, S. Di Cosimo, F. Cognetti, 2008, Breast.

Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.

M. Milella, F. Cognetti, A. Fabi, 2007, The oncologist.

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

D. Amadori, L. Mariani, D. Crivellari, 2007, Breast Cancer Research and Treatment.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

David Grimes, Dominique Maraninchi, Ana Lluch, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

P. Ascierto, A. Testori, E. Simeone, 2014, Journal of Translational Medicine.

HER2 and response to paclitaxel in node-positive breast cancer.

F. Cognetti, Francesco Cognetti, Gianluigi Ferretti, 2008, The New England journal of medicine.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

S. Barni, D. Generali, D. Santini, 2021, npj Breast Cancer.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for “vertical” and “lateral” combination strategies

A. Marchetti, R. Foà, S. Chiaretti, 2012, Journal of Molecular Medicine.

PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.

A. Vecchione, A. Ceribelli, M. Milella, 2004, Anticancer research.

Oligometastatic Breast Cancer: How to Manage It?

F. Cognetti, G. Scambia, I. Paris, 2021, Journal of personalized medicine.

Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

M. Ceppi, F. Puglisi, A. Ardizzoni, 2021, NPJ breast cancer.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

S. Barni, C. Boni, P. Bruzzi, 2015, The Lancet.

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Emilio Bria, Antonello Vidiri, Stefano Telera, 2011, Journal of experimental & clinical cancer research : CR.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

J. Sparano, L. Mauriac, D. Lebwohl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab

R. Labianca, J. Tabernero, F. Cognetti, 2006, Targeted Oncology.

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

F. Cognetti, A. Fabi, P. Malaguti, 2016, Journal of experimental & clinical cancer research : CR.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

L. Crinò, M. Mottolese, F. Cognetti, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and

L. Crinò, M. Mottolese, F. Cognetti, 2010 .

Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer

M. Mandalà, F. Cognetti, A. Fabi, 2005, Breast Cancer Research and Treatment.

Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.

R. Labianca, V. Torri, A. Piga, 2008, Journal of the National Cancer Institute.

HER2/neu role in breast cancer: from a prognostic foe to a predictive friend

F. Cognetti, A. Fabi, G. Ferretti, 2007, Current opinion in obstetrics & gynecology.

Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer

S. Verma, M. Milella, K. Pritchard, 2008, Cancer.

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer.

A. Marchetti, R. Sacco, F. Mucilli, 2009, Lung cancer.

Adjuvant Chemotherapy for Non-small Cell Lung Cancer

M. Milella, F. Cognetti, F. Cuppone, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

G. Arpino, A. Russo, F. Montemurro, 2018, The Lancet. Oncology.

Correlation between efficacy and toxicity in pts with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access programme (EAP).

P. Ascierto, A. Testori, P. Queirolo, 2013 .

Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study

S. Barni, F. Cognetti, F. Petrelli, 2021, Breast Cancer Research and Treatment.

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

S. Barni, D. Generali, D. Santini, 2021, npj Breast Cancer.

Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Journal of oncology.

Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.

F. Cognetti, I. Sperduti, E. Bria, 2006, European journal of cancer.

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis

M. Biffoni, C. Peschle, G. Mariani, 2007, Apoptosis.

Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials

S. Di Cosimo, A. Alimonti, F. Cognetti, 2003, Acta oncologica.

Pregnancy Levels of Estrogen and Progesterone: The Double-Edged Sword

F. Cognetti, G. Ferretti, A. Felici, 2007, Cancer Epidemiology Biomarkers & Prevention.

Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach

M. Caterino, B. Ganeshan, F. Cognetti, 2021, Frontiers in Oncology.

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.

A. Favero, B. Duclos, F. Cognetti, 1996, European journal of cancer.

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.

G. Colucci, F. Cognetti, G. Mantovani, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.

M. Milella, F. Cognetti, P. Carlini, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of 10-Ethyl-10-deaza-aminopterin, a novel antifolate, in patients with advanced and/or recurrent squamous cell carcinoma of the head and neck

J. Verweij, J. Schornagel, J. Armand, 1992 .

Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck

O. Dalesio, F. Cognetti, R. Rosso, 1987, Cancer.

Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines

M. Pino, D. McConkey, J. Abbruzzese, 2006 .

Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.

M. Pino, D. McConkey, J. Abbruzzese, 2006, Cancer research.

The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study

F. Cognetti, A. Fabi, D. Giannarelli, 2022, Frontiers in Oncology.

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab

M. Diodoro, M. Mottolese, A. Torsello, 2010, Journal of Translational Medicine.

Central nervous system as exclusive site of disease in patients with melanoma: treatment and clinical outcome of two cases.

F. Cognetti, V. Ferraresi, Francesco Cognetti, 2005, Melanoma research.

[Immunotherapy in non-small cell lung cancer patients: back to the future.]

P. Marchetti, F. Cognetti, D. Santini, 2019, Recenti progressi in medicina.

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

S. Groshen, L. Collette, M. Parmar, 2021, European urology.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

R. Maria, J. McCubrey, G. Blandino, 2012, Journal of Molecular Medicine.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas

M. Maschio, B. Casini, F. Cognetti, 2019, Journal of Neuro-Oncology.

Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials

M. Milella, F. Cognetti, P. Carlini, 2008, Breast Cancer Research and Treatment.

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas

F. Cognetti, L. Marucci, A. Fabi, 2014, BioMed research international.

The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey

F. Cognetti, D. Giannarelli, G. Costantini, 2021, European Journal of Cancer.

Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey

F. Cognetti, F. Riva, V. Di Noia, 2021, European Journal of Cancer.

The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

F. Cognetti, D. Giannarelli, G. Costantini, 2021, European journal of cancer.

Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials.

M. Gallucci, M. Milella, F. Cognetti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of vinorelbine and thiotepa in metastatic breast cancer.

F. Cognetti, A. Fabi, S. Tomao, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

F. Cognetti, L. Moscetti, P. Carlini, 2005, Cancer Chemotherapy and Pharmacology.

Vitamin E neuroprotection for cisplatin neuropathy

A. Silvani, V. Scaioli, F. Cognetti, 2010, Neurology.

Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials

F. Montemurro, V. Rossi, F. Cognetti, 2019, Cancers.

PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer

M. Todaro, G. Stassi, M. Konopleva, 2017, Scientific Reports.

Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.

M. Milella, F. Cognetti, D. Giannarelli, 2000, American journal of clinical oncology.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

G. Arpino, D. Generali, K. Cannita, 2017, Oncotarget.

Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene–Amplified Breast Cancer Cells

D. Trisciuoglio, G. Zupi, M. Mottolese, 2004, Clinical Cancer Research.

Toxic dermatitis induced by 10‐ethyl‐10‐deazaaminopterin (10‐EdAM), a novel antifolate

J. Verweij, J. Schornagel, F. Cognetti, 1990, Cancer.

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

E. Van Cutsem, L. Dirix, Y. Humblet, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines

G. Bepler, F. Cognetti, A. Fabi, 2011, Cancer Chemotherapy and Pharmacology.

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution

F. Cognetti, P. Carlini, D. Giannarelli, 2021, Clinical Cancer Research.

In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy

G. Bepler, A. Monteiro, M. Schell, 2009, Cancer investigation.

Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study

F. Cognetti, I. Sperduti, F. Cuppone, 2007, Anti-cancer drugs.

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors

M. Mottolese, F. Cognetti, D. Giannarelli, 2006, Anti-cancer drugs.

Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.

M. Milella, F. Cognetti, A. Fabi, 2004, Journal of experimental & clinical cancer research : CR.

Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.

F. Cognetti, A. Fabi, S. Tomao, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study

F. Cognetti, A. Fabi, E. Magnani, 2000, Cancer Chemotherapy and Pharmacology.

Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients.

F. Cognetti, R. Rosso, M. Venturini, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

F. Cognetti, A. Fabi, D. Giannarelli, 2012, BMC Cancer.

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting

L. Mantovani, N. Normanno, L. Capussotti, 2014, PloS one.

Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

P. Muti, M. Milella, F. Cognetti, 2010, Journal of experimental & clinical cancer research : CR.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

M. Marino, M. Mottolese, F. Cognetti, 2013, Expert opinion on pharmacotherapy.

Targeting bone metastatic cancer: Role of the mTOR pathway.

D. Amadori, D. Generali, F. Cognetti, 2014, Biochimica et biophysica acta.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

L. Crinò, P. Bruzzi, F. Cognetti, 2008, Clinical breast cancer.

bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

P. Muti, M. Milella, F. Cognetti, 2010 .

1318PItalian nivolumab expanded access programme in non-squamous non-small cell lung cancer patients: Real-world results in never smokers and EGFR positive patients

E. Vasile, G. Ceresoli, R. Chiari, 2017 .

First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

F. Cognetti, A. Fabi, P. Malaguti, 2016, Journal of Experimental & Clinical Cancer Research.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.

S. Cosimo, M. Pino, M. Mottolese, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer

L. Mauriac, F. Cognetti, M. Marty, 2005 .

672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer

K. Mayne, F. Cognetti, M. Marty, 2003 .

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.

F. Cognetti, D. Giannarelli, F. Pimpinelli, 2021, Annals of Oncology.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

M. Mottolese, M. Milella, F. Cognetti, 2008, Cancer Chemotherapy and Pharmacology.

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

F. Cognetti, M. Pallocca, F. Pimpinelli, 2022, European Journal of Cancer.

Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!

F. Cognetti, D. Giannarelli, F. Pimpinelli, 2022, European journal of cancer.

Narrative medicine: feasibility of a digital narrative diary application in oncology

G. Sanguineti, F. Cognetti, A. Fabi, 2022, The Journal of international medical research.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

S. Cosimo, M. Mandalà, S. Di Cosimo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance.

M. Diodoro, M. Mottolese, A. Torsello, 2008, European journal of cancer.

Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.

F. Cognetti, A. Fabi, S. Fattoruso, 2013, Anticancer research.

A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma

A. Ceribelli, E. Pescarmona, P. Marchetti, 2021, Cancers.

Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.

F. Cognetti, R. Cavaliere, P. Vici, 1995, Journal of the American College of Surgeons.

Re: Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized Trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Re: Ovarian ablation or suppression in premenopausal early breast cancer: results from the International Adjuvant Breast Cancer Ovarian Ablation or Suppression randomized trial.

F. Cognetti, P. Carlini, G. Ferretti, 2007, Journal of the National Cancer Institute.

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

D. Radisky, F. Modugno, P. Visca, 2014, Oncotarget.

Ifosfamide, cisplatin and etoposide combination in locally advanced inoperable non-small-cell lung cancer: a phase II study

M. Milella, F. Cognetti, V. Ferraresi, 1999, British Journal of Cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study.

M. Pino, S. Di Cosimo, F. Cognetti, 2004, Anticancer research.

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease

S. Cosimo, M. Pino, M. Mottolese, 2006 .

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.

A. Rossi, C. Gridelli, A. Ceribelli, 2007, The Lancet. Oncology.

Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.

A. Ballestrero, P. Bruzzi, F. Puglisi, 2021, The Lancet. Oncology.

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

S. Cosimo, M. Milella, F. Cognetti, 2004, Cancer.

Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients

M. Mottolese, F. Cognetti, A. Fabi, 2006, Cancer Chemotherapy and Pharmacology.

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

F. Puglisi, G. Arpino, D. Generali, 2021, ESMO open.

A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 2004, Cancer Chemotherapy and Pharmacology.

Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity

F. Cognetti, I. Sperduti, F. Cuppone, 2009, Anti-cancer drugs.

The treatment of 48 patients affected by ovarian carcinoma at stages III and IV F.I.G.O.

L. Villani, F. Cognetti, P. Margariti, 1981, European journal of gynaecological oncology.

Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial

S. Pignata, G. Signoriello, F. Cognetti, 2008, Oncology.

Correction: Transforming growth factor α expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines (Cancer Research (2006) 66, 7, (3802-3812))

M. Pino, D. McConkey, J. Abbruzzese, 2010 .

Journal of Experimental & Clinical Cancer Research Targeting Targeted Agents: Open Issues for Clinical Trial Design

M. Milella, F. Cognetti, M. Di Maio, 2009 .

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials

M. Aapro, F. Puglisi, M. Milella, 2011, Journal of experimental & clinical cancer research : CR.

Short communication A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma

J. Verweij, J. Schornagel, F. Cognetti, 1994 .

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer

G. Blandino, M. Diodoro, S. Shirasawa, 2020, Communications Biology.

BRAF status modulates Interelukin-8 expression through a CHOP-dependent mechanism in colorectal cancer

G. Blandino, M. Diodoro, S. Shirasawa, 2020, Communications biology.

Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.

M. Pino, A. Gabriele, F. Cognetti, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential chemotherapy in nonsmall‐cell lung cancer

M. Caterino, A. Ceribelli, M. Pino, 2007, Cancer.

More information, more choice: an Italian database for oncology patients.

F. Cognetti, M. Montella, W. Russell-Edu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Paolo Carlini, S. Di Cosimo, F. Cognetti, 2003, Drugs of today.

Taxanes as primary chemotherapy for early breast cancer

M. Milella, F. Cognetti, P. Carlini, 2008, Cancer.

Re: Treatment of human epidermal growth factor receptor 2 overexpressing breast cancer xenografts with multiagent human epidermal growth factor receptor targeted therapy.

F. Cognetti, G. Ferretti, A. Felici, 2007, Journal of the National Cancer Institute.

A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule

F. Cognetti, T. Gamucci, M. Nardi, 2001, Cancer Chemotherapy and Pharmacology.

Ifosfamide and Epirubicin Combination in Untreated Sarcomas: Two Treatment Schedules

F. Cognetti, C. Nardoni, P. Papaldo, 2001, Oncology Research and Treatment.

Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?

A. Vecchione, S. Di Cosimo, A. Alimonti, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Self-monitoring versus standard monitoring of oral anticoagulation.

M. Mandalà, F. Cognetti, P. Carlini, 2007, Thrombosis research.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

F. Cognetti, A. Fabi, M. Infante, 2019, Journal of experimental & clinical cancer research : CR.

Old age: biologic versus chronologic.

M. Milella, F. Cognetti, C. Nuzzo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?

A. Alimonti, F. Cognetti, G. Ferretti, 2006, British Journal of Cancer.

Celecoxib combined with fixed dose-rate gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC)

A. Ceribelli, M. Milella, F. Cognetti, 2005 .

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

M. Mottolese, A. Torsello, F. Cognetti, 2010, British Journal of Cancer.

Weekly Docetaxel in Pretreated Metastatic Breast Cancer Patients: A Phase I-II Study

S. Barni, L. Frontini, M. Milella, 2005, Oncology.

Long‐term survival in locally advanced oral cavity cancer: An analysis of patients treated with neoadjuvant cisplatin‐based chemotherapy followed by surgery

F. Cognetti, P. Carlini, D. Giannarelli, 2005, Head & neck.

Accelerated Hyperfractionated Radiotherapy and Concurrent Protracted Venous Infusion Chemotherapy in Locally Advanced Head and Neck Cancer

S. Arcangeli, F. Cognetti, E. de' Campora, 2002, American journal of clinical oncology.

Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues

A. Rossi, S. Verma, G. Tonini, 2008 .

Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial

M. Ceppi, F. Puglisi, O. Garrone, 2019, International journal of cancer.

The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy.

F. Cognetti, A. Fabi, L. Moscetti, 2019, Current Problems in Cancer.

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

F. D. De Braud, R. Miceli, F. Atzori, 2021, Expert review of clinical pharmacology.

Molecular and genetic bases of pancreatic cancer.

M. Pino, M. Milella, F. Cognetti, 2012, Current Drug Targets.

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study.

U. Capitanio, F. D. De Braud, R. Miceli, 2019, European urology oncology.

Retroperitoneal liposarcoma with metastasis to both orbits: an unusual metastatic site.

F. Cognetti, A. Fabi, V. Ferraresi, 2005, Anticancer Research.

Multigene tests for breast cancer: the physician’s perspective

S. Barni, G. Pruneri, D. Santini, 2021, Oncotarget.

Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity

A. Silvani, F. Cognetti, A. Pace, 2007 .

Nephroblastoma in the adult.

F. Cognetti, S. De Marco, C. F. Pollera, 1999, Medical and pediatric oncology.

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

F. Cognetti, A. Fabi, P. Malaguti, 2013, Anticancer research.

MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program

D. Galetta, L. Crinò, M. Tiseo, 2017 .

Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?

M. Pino, M. Milella, F. Cognetti, 2007, Cancer.

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients

M. Caterino, M. Mottolese, F. Cognetti, 2015, Drug design, development and therapy.

Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional-cell carcinoma (TCC) of the bladder in patients (pts) enrolled in the Italian National Research Council (CNR) phase III randomized trial comparing adjuvant cisplatin-gemcitabine (PG) vs observation (OBS) after radic

M. Gallucci, F. Cognetti, F. Boccardo, 2005 .

Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck.

F. Cognetti, M. Merlano, F. Scasso, 1994, European journal of cancer.

Transforming growth factor-beta signaling and regulatory T cells.

M. Mandalà, F. Cognetti, G. Ferretti, 2007, Journal of Clinical Oncology.

Prostate cancer: the role of hormonal therapy.

F. Cognetti, P. Carlini, E. Bria, 2005, Journal of experimental & clinical cancer research : CR.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)-Are there differences of concern?

R. Gralla, M. Milella, F. Cognetti, 2011, Journal of Clinical Oncology.

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

R. Maria, J. McCubrey, G. Blandino, 2012, Journal of molecular medicine.

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

L. Mauriac, F. Cognetti, M. Marty, 2004 .

A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).

A. Ceribelli, M. Pino, F. Cognetti, 2008, Lung cancer.

Original article Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients

F. Cognetti, R. Rosso, M. Venturini, 2005 .

Chemotherapy-induced amenorrhea in early breast cancer.

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

S. Di Cosimo, F. Cognetti, A. Fabi, 2006, Breast.

Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer

A. Ceribelli, M. Milella, F. Cognetti, 2005, Journal of Cancer Research and Clinical Oncology.

The European Ipilimumab Expanded Access Programme (EAP): Efficacy and Safety Data from the Italian Cohort of Patients with Pretreated, Advanced Melanoma

P. Ascierto, A. Testori, P. Queirolo, 2012 .

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .

Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.

Angela Ferrari, F. Cognetti, C. Catricalà, 2006, Anticancer research.

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

M. van Glabbeke, J. Bourhis, M. Bolla, 2004, The New England journal of medicine.

Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC)

S. Cosimo, M. Mottolese, F. Cognetti, 2007 .

Fixed dose‐rate gemcitabine infusion as first‐line treatment for advanced‐stage carcinoma of the pancreas and biliary tree

S. Di Cosimo, M. Milella, F. Cognetti, 2005, Cancer.

Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.

Stephen L. Abrams, J. McCubrey, W. Chappell, 2014, Current pharmaceutical design.

Plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: Association with single nucleotide polymorphisms (SNPs) of CYP19A1.

C. Boni, R. Ponzone, F. Cognetti, 2009, Journal of Clinical Oncology.

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001).

J. Baselga, F. Rojo, J. Arribas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models

A. Scarpa, V. Corbo, S. Shirasawa, 2018, Journal of Experimental & Clinical Cancer Research.

Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?

M. Milella, F. Cognetti, A. Fabi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer

V. Torri, G. Scagliotti, D. Galetta, 2019, Annals of Oncology.

Cancer in the elderly: why so badly treated?

M. Aapro, S. Monfardini, F. Cognetti, 1990, Lancet.

p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.

E. Pescarmona, M. Mottolese, F. Cognetti, 2020, Clinical breast cancer.

Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.

P. Ascierto, E. Simeone, P. Queirolo, 2023, European Journal of Cancer.

Non-small cell lung cancer: early stages.

U. Pastorino, A. Ceribelli, F. Cognetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.

V. Corbo, M. Milella, L. Ciuffreda, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of ' early phases ' : are traditional phase I studies with new drugs reliable ?

M. Milella, F. Cognetti, P. Carlini, 2015 .

Bone and lung metastases from intracranial meningioma.

F. Cognetti, A. Fabi, A. Vidiri, 2006, Anticancer research.

Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women

M. Milella, F. Cognetti, A. Fabi, 1999, Breast Cancer Research and Treatment.

Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab‐Based Therapy beyond Progression in HER‐2 Positive Metastatic Breast Cancer 1

M. Mottolese, F. Cognetti, A. Fabi, 2010, The breast journal.

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients.

M. Milella, F. Cognetti, I. Sperduti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

A. Ceribelli, G. Tortora, M. Milella, 2013, Expert opinion on drug discovery.

Advances in Tumor-Stroma Interactions: Emerging Role of Cytokine Network in Colorectal and Pancreatic Cancer

M. Milella, L. Ciuffreda, F. Cognetti, 2019, Journal of oncology.

Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.

A. Testori, P. Gascón, C. Garbe, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

of chemotherapy-induced alopecia with paclitaxel in a case of hypothyroidism:

S. Cosimo, F. Cognetti, A. Fabi, 2003 .

COX-2 targeting in cancer: a new beginning?

M. Milella, F. Cognetti, A. Fabi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy

J. Baselga, F. Rojo, S. Cosimo, 2005 .

Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents.

C. Porta, G. Tortora, M. Milella, 2013, Clinical genitourinary cancer.

Is There a Right-Sided Shift for Colorectal Cancer in Women Compared with Men?

L. Kelemen, F. Cognetti, A. Felici, 2006, Cancer Epidemiology Biomarkers & Prevention.

Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck.

F. Cognetti, J. Vermorken, A. Kirkpatrick, 1986, European journal of cancer & clinical oncology.

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

S. Barni, C. Boni, P. Bruzzi, 2015, The Lancet.

New drugs in the treatment of recurrent or metastatic cervical cancer.

F. Cognetti, A. Savarese, 2003, Critical reviews in oncology/hematology.

Maintenance of antiemetic effect of a metoclopramide-dexamethasone combination during subsequent cisplatin courses.

F. Cognetti, P. Carlini, E. Ruggeri, 1986, Oncology.

CPT11 alternating with 5 fluorouracil (5 FU) folinic acid (FA): A multicentre phase II study in 1st line chemotherapy (CT) of metastatic colorectal cancer (CRC): Preliminary results

L. Dirix, Y. Humblet, F. Cognetti, 1997 .